Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.55 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
| ▸ | AKT2 | P31751 | 2/20 | 0.53 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094224 | 0.92 | AKT1 (0.53) | OPRM1AKT1AKT2AKT3CHRM1 | |
| SCHEMBL3094304 | 0.91 | CHRM1 (0.53) | OPRM1SSTR5AKT1AKT2AKT3 | |
| SCHEMBL3098579 | 0.91 | AKT1 (0.51) | OPRM1AKT1AKT2AKT3CHRM1 | |
| SCHEMBL3081955 | 0.90 | AKT1 (0.51) | OPRM1SSTR5AKT1AKT2AKT3 | |
| SCHEMBL3097977 | 0.90 | OPRM1 (0.51) | OPRM1AKT1AKT2AKT3CHRM1 | |
| SCHEMBL3138205 | 0.88 | OPRM1 (0.54) | OPRM1CHRM1OPRL1OPRK1HTR1A | |
| SCHEMBL3104467 | 0.88 | AKT1 (0.50) | OPRM1SSTR5AKT1AKT2AKT3 | |
| SCHEMBL3094342 | 0.88 | SSTR5 (0.52) | OPRM1SSTR5AKT1AKT2AKT3 | |
| SCHEMBL3093187 | 0.88 | AKT1 (0.50) | OPRM1SSTR5AKT1AKT2AKT3 | |
| SCHEMBL3098723 | 0.88 | AKT1 (0.49) | OPRM1AKT1AKT2AKT3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | claimed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | claimed |
| EP-2142528-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | claimed |
| WO-2008122510-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | claimed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | claimed |
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | disclosed |
| EP-2142528-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008122510-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | SSTR5, SSTR3, SSTR1 | OPRM1 706/4885SSTR5 1/4885AKT1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.